* Supported by the Allen P. and Josephine B. Green Foundation, and the Teagle Foundation, Inc. This paper was presented in part at the Cleveland Meeting of the American Association of Neurological Surgeons, April 14, 1969. was 1.4% while the morbidity was 4.6%, except for disturbances in speech, balance and gait, and mental problems. Here, the range was estimated from an earlier publication at 8% to 13%. 1~ However, the symptoms mentioned above in connection with pyramidal tract surgery have similarly remained recalcitrant to basal ganglia attack, and again, the inexorable downhill course for many patients continued unaltered. For such individuals, the long-term functional resuits were in no way comparable to those obtainable in persons simply with disabfing tremor, rigidity, and poor movements, especially when these symptoms were largely unilateral.
Medical and drug treatment had always been disappointing, serving to give some relief to only 25% to 30% of patients. 6 These results accrued with both natural and synthetic anticholinergic drugs, such as atropine and its derivatives, or trihexyphenidyl and related substances, antihistamines, and stimulants of the amphetamine type. None of these medications halted or even slowed the progressive course of the disease, and disabling symptoms continually appeared or advanced until the patient was unable to help himself in any way. Advanced cases showed premature aging, neurogenic bladder with overflow incontinence, difficulty with swallowing, inability to walk, and progressive mental deterioration of organic type. Drooling of saliva, and problems, of voice, speech, and even language became manifest in the late stages. Physical therapy and rehabilitation including speech therapy have likewise proven futile in these advanced cases, although some benefit has been obtained in earlier less-involved patients.
Background of Therapy with L-Dopa
The chief basis on which a rationale for treatment of parkinsonism with L-dopa rests is the finding by Hornykiewicz and 275 associates 9 as early as 1960 that dopamine is virtually absent from the corpus striatum and substantia nigra in parkinsonian brains obtained at autopsy. They and others have also found abnormalities of other catechole amines and their metabolites in brain, blood, and urine. Much evidence, too, points to a nigro-striatal dopaminergic pathway. The importance of brain dopamine is further emphasized by the well-known fact that reserpine, which induces parkinsonian signs, depletes the brain of dopamineY Beneficial effects in parkinsonian patients from treatment with L-dopa were reported early, with reference especially to bradykinesia and rigidity. 1,7,9 Some investigators disagreed, s More definitively favorable results were obtained in a series of 28 cases, some followed for 2 years by Cotzias and associates, 4,5 who noted also that toxic effects were more frequent when they used the racemic mixture of both D and L-dopa. Other clinicians 14 have followed suit with their own series of cases. There is general agreement that the beneficial effects of L-dopa surpass those of any drugs used hitherto, and the improvement is especially noticeable for symptoms such as bradykinesia, balance, posture, gait, facial expression, and general well-being, not ordinarily susceptible to surgical treatment. However, improvement has likewise been reported for rigidity and tremor, although less dramatically. Toxic side-effects, including nausea, vomiting, and anorexia, fall in blood pressure with cardiac dysrhythmia and fainting, abnormal choreiform movements, and mental changes, have often limited the benefits obtainable.
Objectives of This Study
Our purpose was twofold: 1 ) to determine whether L-dopa provides a significant new treatment for Parkinson's disease without producing harmful toxic effects; and 2) to determine the optimal therapeutic relationship between L-dopa and cryosurgical thalamectomy.
Materials and Methods
We began our program of L-dopa treatment for parkinsonism in November, 1968, and currently have under treatment approximately 120 patients. Ninety-one have been receiving the drug for more than a month Waltz and Cooper and these form the basis for this preliminary report. The others have been excluded because the lapsed time is too short to permit reasonable evaluation. Eight patients have been treated for more than 4 months, 24 for more than 3 months, 29 more than 2 months, and 30 for over 1 month. Males and females are approximately equally represented, and the age range is similar to that of the population previously reported for our surgical series.
However, there is an increasing proportion of persons in the 8th decade while at the same time a greater number of markedly advanced and almost totally disabled persons are included. This, of course, is because patients and families as well as referring physicians will consider medical treatment where they would otherwise reject even a consideration of surgery. Thus, only one patient was less than 40 years of age, 14 were between 40 and 50, 21 between 50 and 60, 33 between 60 and 70, and 22 between 70 and 80 years of age. Only 20 had been ill for less than 5 years, 43 from 5 to 10 years, 20 from 10 to 15 years, and 8 had been afflicted for more than 15 years.
The drug was administered orally in the form of a 500 mg. tablet for most patients, with some, however, receiving a 250 mg capsule where tolerance was low. The dosage was built up slowly, as a rule from 500 mg per day to a level of 3 to 5 gm each day, usually in four divided doses spaced throughout the waking portion of the day. It was often given with meals or a small amount of milk to reduce the frequent nausea and vomiting encountered. A dosage of 3 gm per day was usually reached within a week, provided the patient was able to tolerate the drug. Most patients noted no effect, beneficial or toxic, from that dosage, but some were more sensitive and reacted strongly to 1 or 2 gm a day. Some required a larger amount, up to 8.5 gm per day in one case. About half the patients noted significant effects, both beneficial and toxic, at 4 to 5 gm per day. All but one of the patients were treated at first in the hospital as regular inpatients and were carefully monitored clinically and by laboratory study. Once the dosage was stabilized, the patient was discharged to continue treatment on an outpatient basis provided there were no toxic ef-
